Eric Goffin: Complement Activation Is the Hallmark of Atypical HUS
Eric Goffin, Head of the Nephrology at Cliniques Universitaires St-Luc, shared on LinkedIn:
”Uncontrolled complement activation: the hallmark of atypical hemolytic uremic syndrome (aHUS).
This rare but severe condition causes microvascular thrombosis, hemolysis, and kidney failure. Understanding why and who is affected is key to saving lives.
A new study from the Belgian cohort of the Global aHUS Registry just brought valuable answers !
- Massart A. et al., Journal of Nephrology (2025)
- Key insights:
- 121 Belgian patients (≈10.4 per million)
- 58% were women
- 1 in 3 carried a complement gene variant or anti-CFH antibodies
- Main genes involved: CFH, C3, and CD46
These real-world data deepen our understanding of aHUS and highlight the importance of personalized diagnostics and targeted complement therapies.”
Read the full article here.
Title: Clinical and genetic characteristics of patients diagnosed with atypical hemolytic uremic syndrome (aHUS): epidemiological data from the Belgian cohort of the Global aHUS Registry
Authors: Annick Massart, Laurent Weekers, Kathleen J. Claes, Tess Van Meerhaeghe, Evelien Snauwaert, Djalila Mekahli, Eric Goffin, Laure Collard, Nathalie Godefroid, Brigitte Adams, Stefan Van Cauwelaert, Koenraad Van Hoeck, Sebastien Block, Imad Al-Dakkak, Karin Dahan, Patrick Stordeur, Johan Vande Walle
Stay updated with Hemostasis Today.
-
Nov 3, 2025, 08:23The 1st Participant in A New CHECK-NIRS Clinical Study is Enrolled!
-
Nov 3, 2025, 08:15Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
-
Nov 3, 2025, 07:10Lisa Shea Shares Key Takeaways from NORD Summit 2025
-
Nov 3, 2025, 06:49Darshan Doshi on Results of iMODERN and ILIAS ANOCA Studies Presented at TCT 2025
-
Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 3, 2025, 04:56Nirupama Ramadas and Erica Sparkenbaugh on Thromboinflammation in SCD
-
Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
-
Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 3, 2025, 09:24Stephen Cornelissen: It’s Not Just About Emergencies — It’s About Everyday Care, Chronic Conditions and Hope
-
Nov 3, 2025, 06:57Maria Elisa Mancuso Reflects on 2025 Annual Congress of the Italian Association of Hemophilia Centres
-
Nov 3, 2025, 05:46Chandra Viswanathan: When Blood Safety Fails, We All Bleed - A Call for Reform and Responsibility
-
Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
-
Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry